NOVO NORDISK is now bigger than Tesla. Due to Wegovy
Market valuation now US$566 Bn, number 12 in the world.
NOVO is conscious of the vulnerability of being exposed to a single therapeutic area.
The NOVO CEO said that the company is looking beyond diabetes and weight-loss treatment to include cardiovascular disease.
A portfolio manager commented that the cardiovascular field makes sense because it ties in with the clear cardiovascular benefits of Wegovy
Makes sense to me too. Potential partners must be conscious of Revascor. Competitively so
C'mon over NOVO. Get in first
Cell Therapy News/Articles, page-17494
-
- There are more pages in this discussion • 355 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.000(0.00%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3750 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 23722 | 6 |
View Market Depth
| Last trade - 09.51am 30/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable